Allergan

Pharama Tech | November 23, 2016

Allergan announced that it has completed the acquisition of Chase Pharmaceuticals Corporation, a biopharmaceutical company specializing in the development of improved treatments for neurodegenerative disorders including Alzheimer's disease. Allergan has paid an upfront fee of $125 million (subject to certain adjustments) to Chase. There will be additional potential regulatory and sales milestone payments related to Chase's lead compound, CPC-201, and certain backup compounds....

Allergan | December 22, 2016

US-based drugmaker Allergan has signed an agreement to acquire Acelity’s regenerative medicine unit LifeCell in a deal valued at $2.9bn.The acquisition will combine LifeCell's business, including its portfolio of dermal matrix products with Allergan's portfolio of medical aesthetics, breast implants and tissue expanders....

Fierce Pharma | February 13, 2017

When the SEC criticized Valeant Pharmaceuticals over its use of non-GAAP reporting, it seemed like a regulator barking at a company known for pushing the limits. But now the agency has fired a warning shot across the bow of the industry, saying in a letter to Allergan that it intends to examine how the industry is potentially exploiting the practice....

The Pharma Letter | April 07, 2017

Botox (onabotulinumtoxinA), a treatment which made its name for its aesthetic potential in reducing facial wrinkles, is to be taken into Phase III trials in major depressive disorder (MDD)....